Diversifying to Conquer: Fortress Biotech (FBIO) Partnering Expansion Driving Progress in Cancer Immunotherapy and Rare Disease TherapeuticsBenzinga • 06/03/21
Fortress Biotech to Participate in Three June 2021 Virtual Investor ConferencesGlobeNewsWire • 06/01/21
REPEAT -- Fortress Biotech Reports First Quarter 2021 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 05/17/21
Fortress Biotech Reports First Quarter 2021 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 05/16/21
Fortress Biotech Announces Exclusive License Agreement With Fuji Yakuhin to Develop Dotinurad in North America and EuropeGlobeNewsWire • 05/10/21
Zacks Earnings ESP: A Better Way to Find Earnings Surprises for MedicalZacks Investment Research • 05/07/21
Is the Options Market Predicting a Spike in Fortress Biotech (FBIO) Stock?Zacks Investment Research • 04/12/21
Fortress Biotech (FBIO) Surges 11.5%: Is This an Indication of Further Gains?Zacks Investment Research • 04/12/21
Fortress Biotech to Participate in the 20th Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/07/21
Journey Medical Corporation Enters $7.5 Million Line of Credit Agreement with East West BankGlobeNewsWire • 04/05/21
Fortress Biotech's Partner Firm Expands Footprint In Dermatology With Qbrexza AcquisitionBenzinga • 04/01/21
Journey Medical Corporation Enters into a Definitive Agreement with Dermira, Inc., a Wholly-Owned Subsidiary of Eli Lilly and Company, to Acquire QBREXZA®GlobeNewsWire • 04/01/21
Fortress Biotech Reports Record 2020 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 03/31/21
Fortress Biotech's Partner Company, Journey Medical Corporation, In-licenses and Launches Accutane® for the Treatment of Severe Recalcitrant Nodular AcneGlobeNewsWire • 03/22/21
Will Fortress Biotech (FBIO) Report Negative Q4 Earnings? What You Should KnowZacks Investment Research • 03/08/21
Caelum Biosciences Announces Collaborations with the Amyloidosis Advocacy Community and Support of Amyloidosis Awareness MonthGlobeNewsWire • 03/01/21